Neurolutions

Neurolutions occupies a specialized position at the intersection of medical devices, neurotechnology, and digital therapeutics. Its focus is narrower than broad neurological-care platforms: the company targets chronic stroke survivors who need to recover arm and hand function, using IpsiHand as a non-invasive, thought-controlled rehabilitation system. The product's reported FDA De Novo authorization and Breakthrough Medical Technology status provide meaningful regulatory differentiation, while the 2024 CMS decision addresses a practical barrier that many clinically promising rehabilitation technologies face: reimbursement and adoption. The company therefore competes less as a general-purpose software provider and more as a clinically oriented device business requiring evidence, regulatory clearance, and provider engagement. Its market position is also shaped by the 2025 combination with Kandu Health, which may broaden the commercial and care-delivery context around its stroke-rehabilitation technology. The main constraints are likely the specialized patient population, clinical-sales cycle, reimbursement complexity, and need to demonstrate durable functional outcomes at scale.

Neurolutions has followed a long clinical-development trajectory rather than a rapid software-growth pattern. Founded in 2007, the company developed technology originating from research associated with Eric Leuthardt's laboratory at Washington University in St. Louis and built its strategy around a non-invasive brain-computer interface for stroke rehabilitation. It raised a $100,000 seed round in 2012, followed by a $1.15 million venture round in 2015. A further venture round was recorded in 2018 without a disclosed amount, before the company raised $26.55 million on Mar 14, 2025. That financing brought cumulative recorded funding to $27.8 million and represented the clearest capital inflection point in the history provided. Commercial momentum also became more visible after IpsiHand received FDA De Novo authorization and was launched commercially in 2023. The 2024 CMS decision improved the product's reimbursement prospects, while the 2025 merger with Kandu Health created a new organizational platform for continued commercialization. The available employee data indicates a compact organization of roughly 11 to 50 people, with eight current positions listed. There is no confirmed hiring surge or workforce expansion trend, so future growth is more likely to depend on commercialization, reimbursement, and integration execution than on rapid headcount scaling.